Clinical & Translational Research

Clinical & Translational Research
Olufunmilola Abraham
Olufunmilola Abraham, Assistant Professor

Research interests include medication use in adolescents and young adults, technology use and game-based learning, developing medication safety innovations in adolescent health care, and pharmacist-led interventions in medication management.

John Dopp
John Dopp, Associate Professor (CHS)

Clinical practice: Treatment of sleep disorders and management of hypertension and cardiovascular disease.  Identification and management of sleep problems in college athletes.

Research Interests: Mechanisms for cardiovascular disease in patients with obstructive sleep apnea and identification of interventions and therapies to minimize and prevent cardiovascular complications.

Barry Gidal
Barry Gidal, Professor (CHS) and Chair

Clinical Practice: Provision of pharmaceutical care to patients with epilepsy.

Research Interests: Pharmacokinetics, pharmacodynamics, and the metabolic effects of anticonvulsant medications.

Mary Hayney
Mary Hayney, Professor (CHS)

Clinical Practice: Lung transplantation.

Research Interests: Host response to vaccination and protective effects, especially as they relate to immunosuppressed individuals.

Warren Rose
Warren Rose, Associate Professor (CHS) (Drug Discovery)| Rose Lab website

Research Interests: • Antimicrobial resistance and pharmacodynamics  • Antimicrobial effects on host-pathogen interactions

Christine Sorkness
Christine Sorkness, Professor (CHS)

Research Interests: Evaluating the efficacy and safety of therapeutic agents for asthma and allergic diseases.

Ronald Sorkness
Ronald Sorkness, Professor (CHS)

Research Interests: Mechanisms of obstructive airway disease and virus-induced airway dysfunction.

Cody Wenthur
Cody Wenthur, Assistant Professor (Drug Action)| Wenthur Lab Website

Elucidating how neurochemical systems interact to support maladaptive learning and synaptic plasticity; Development of novel bioconjugates to probe the effects of psychoactive substances; Identifying biomarkers of ongoing drug abuse; Assessing barriers to implementation of novel addiction treatment paradigms.

^ Back to top